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Abstract
Introduction: Pulmonary arterial hypertension (PAH) is a serious and often fatal complication of systemic lupus erythematosus 
(SLE). Because the diagnosis of PAH often is made years after symptom onset, early diagnostic strategies are essential. Doppler 
echocardiography currently is considered the noninvasive screening test of choice for evaluating pulmonary hypertension.
Aim: Screening for asymptomatic pulmonary hypertension in systemic lupus erythematosus patients using Doppler echocardiography, 
and correlating it with inflammatory parameters of the disease.
Patients and methods: Doppler echocardiography was performed in 74 patients with systemic lupus erythematosus over one year 
(66 adult and 8 juvenile), adult SLE included 57 patients with adult-onset and 9 patients with childhood-onset. Pulmonary hypertension 
was diagnosed if the peak systolic pressure gradient at the tricuspid valve was more than 30 mmHg. All patients were subjected to full 
history taking, rheumatological examination, laboratory studies and chest x-ray.
Results: In seventy four SLE patients, the pulmonary hypertension was detected in 8 patients (10.8%), 7 adult-onset SLE patients 
(aged from 19 to 30 years) and 1 juvenile SLE (aged 12 years). The range of pulmonary artery systolic pressure was 34–61.2 mmHg 
(43.19 ± 9.28). No significant differences between patients with and those without pulmonary hypertension as regard clinical features. 
Significantly higher frequencies of rheumatoid factor and anti-cardiolipin antibodies were found in patients with pulmonary hypertension 
versus those without (P = 0.02, P = 0.008 respectively). Positive rheumatoid factor and ACL were significantly associated with occurrence 
of PAH in SLE (P = 0.007, P = 0.006 respectively). No significant correlations were found between pulmonary artery pressure, disease 
duration, SLE Disease Activity Index (SLEDAI), ESR, and anti-ds DNA.
Conclusion: Patients with SLE have an increased risk of pulmonary arterial hypertension. Echocardiography should be used as a 
screening tool in patients at high risk for development of pulmonary hypertension. Positive anti-cardiolipin antibodies and rheumatoid 
factor were significant predictors of pulmonary hypertension in our study.
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Introduction
Systemic lupus erythematosus (SLE) is an autoim-
mune  disease  of  unknown  origin  characterized  by 
inflammation  of  multiple  organs  (kidneys,  brain, 
heart, liver, lungs, joints, muscles, skin, etc.).1
The  kidney  has  usually  been  considered  the 
most  frequently  affected  organ  in  systemic  lupus 
erythematosus, the heart and the pulmonary vessels, 
however, may also be seriously involved.2
Pulmonary  involvement  is  relatively  frequent 
in  adult  patients  rather  than  children.3  Pulmonary 
hypertension  is  the  most  severe  forms  of  lupus 
associated  pulmonary  involvement,  although  they 
occur infrequently in children with SLE.4
Although  several  mechanisms  are  involved  in 
pathogenesis  of  pulmonary  hypertension  in  SLE, 
the real causes are yet unknown. The hypothesis of 
pulmonary vasculitis, with deposits of immunocom-
plexes  and  complements  on  the  pulmonary  artery 
walls, thromboembolic blockage in pulmonary ves-
sels,  possibly  related  to  antibodies  (anticardiolipin 
antibody and lupus anticoagulant), and vasospasms, 
are suggested by a greater frequency of Raynaud’s 
phenomenon in these patients.5
The prevalence of pulmonary arterial hypertension 
(PAH) in patients with lupus is largely unknown, but 
has been reported to approximate 6%–15% in adult 
patients, in whom it is most commonly associated 
with Raynaud’s phenomenon.6
There have been very few studies addressing the 
prevalence of PAH in childhood-onset SLE, which is 
reported to approximate 4%–8% using transthoracic 
echocardiography.7
The  determination  of  the  real  prevalence  and 
magnitude  of  pulmonary  hypertension  in  SLE  has 
been difficult over the years due to the fact that the 
only method with sufficient sensitivity for determining 
pulmonary pressures and confirming the existence of 
pulmonary hypertension has been the catheterization 
of  the  right  chambers  with  direct  measurement  of 
pulmonary pressures. The advent of two-dimensional 
Doppler echocardiography, a method thought to be 
of similar sensitivity as right chamber catheterization 
for measuring pulmonary pressure, allowed the study 
of  a  greater  number  of  patients,  with  or  without 
symptoms.5
Pulmonary hypertension is often silent, with the 
development of clinical symptoms often signaling the 
presence of advanced disease, associated with poor 
survival. This has prompted the need for methods of 
detecting PAH, including annual echocardio-graphic 
screening of asymptomatic individuals with systemic 
autoimmunity.8
The sensitivity and specificity of Doppler echocar-
diography (DE) for estimating pulmonary artery pres-
sure are 0.79 to 1.0 and 0.68 to 0.98, respectively.9 
DE can evaluate the degree of PH, prognosticating 
variables (RA and RV enlargement, pericardial effu-
sion, RV ejection fraction), and other potential causes 
of PH (left ventricular systolic/diastolic dysfunction, 
valvular heart disease, and intracardiac shunting).10
The aim of this study was to screen for asymp-
tomatic  pulmonary  hypertension  in  systemic  lupus 
erythematosus using Doppler echocardiography, and 
to correlate it with inflammatory parameters of the 
disease.
patients and Methods
Study population
This  is  a  cross-sectional  study  conducted  on  SLE 
patients attending outpatient clinic of Rheumatology 
and  Rehabilitation  Department  at  Minia  university 
Hospital,  Egypt,  over  one  year.  All  patients  were 
females  and  met  the  1982  American  College  of 
Rheumatology  revised  criteria  for  SLE11  with 
no  overlap  syndrome.  None  of  the  patients  were 
previously treated with medication correlated to PAH. 
Informed consent was obtained from all patients before 
entering the study. Seventy four female SLE patients 
were recruited, 66 adults (aged from 19 to 45 years), 
and 8 children (aged from 11 to 15 years). All patients 
were asymptomatic for pulmonary hypertension.
Clinical evaluation
All the patients were subjected to a thorough history 
taking,  general  examination,  and  rheumatological 
evaluation  which  included  the  assessment  of  SLE 
Disease Activity Index (SLEDAI).12
Laboratory studies
ESR  was  measured  using  Westergren  method  and 
Rheumatoid factor was performed using Latex fixation 
test.  Antinuclear antibody (ANA), anti-double stranded 
DNA antibody (anti-dsDNA), and IgG anti-cardiolipin 
antibodies (ACL antibodies) were assayed by immuno-
fluorescence  technique  and  ELISA.  Other  routine Asymptomatic pulmonary hypertension in SLe
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  laboratory  tests  as  complete  blood  picture,  renal 
function  test,  urinalysis  (for  pyuria,  hematuria, 
casts), and 24-hour urine for protein were done for 
all patients.
Chest x-ray
A-P and lateral views were done for all patients to 
exclude evidence of parenchymal lung disease.
echocardiographic evaluation
Two-dimensional (2D), M-mode, color flow mapping 
and  spectral  Doppler  echocardiography  were  done 
using a Vivid 3 Expert GE echocardiography machine 
(GE  vingmed  ultrasound,  Horten,  Norway,  model 
vivid 3 Expert), with a 5 MHz transducer for children 
patients. Patients were examined in the parasternal 
long and short axis, and four chamber projections. 
Special attention was given to the detection of tricus-
pid regurgitation.
To  estimate  pulmonary  artery  systolic  pressure 
(PASP),  the  maximum  transtricuspid  pressure 
gradient was calculated using the simplified Bernoulli 
equation.13,14  The  estimate  of  right  atrial  pressure, 
10  mmHg,  was  added  to  the  pressure  gradient  to 
calculate  the  right  ventricular  systolic  pressure, 
which  was  considered  equal  to  the  PASP  in  the 
absence  of  right  ventricular  outflow  obstruction. 
The Doppler recordings were reviewed by at least one 
echocardiographer who had no previous knowledge of 
the patient. Right ventricular dilatation was defined as 
the ventricular area greater than the left ventricular area 
obtained by planimetry from the apical four-chamber 
view. Right ventricular dilatation with flattening of the 
ventricular septum was considered indicative of right 
ventricular  overload.  Pulmonary  hypertension  was 
diagnosed if the peak systolic pressure gradient at the 
tricuspid valve was more than 30 mmHg.
The  severity  of  PH  is  classified  as:  mild 
(PASP , 45 mmHg), moderate (PASP from 45 to 
59 mmHg) or severe (PASP . 60 mmHg).13
Accordingly, patients enrolled in our study were 
divided into two groups:
Group I: Patients with PAH.
Group II: Patients without PAH.
Statistical analysis
Statistical analysis was undertaken using an SPSS 11 
database. Quantitative variables such as pulmonary 
function  tests  were  represented  by  mean  ±  SD. 
Qualitative  variables,  such  as  symptoms,  age,  sex 
were  represented  by  numbers  and  percentages. 
  Student’s  t-test  (t)  was  used  when  comparing  the 
means  of  quantitative  variables.  Chi-squared  test 
(x2) was used to compare frequencies (numbers and 
percentages) for qualitative variables.   Correlations 
between variables were assessed with Pearson test. 
Odds  ratios  (OR)  and  95%  confidence  intervals 
(95% CIs) were calculated. Linear regression analy-
sis was used to examine the predictors contributing 
to PAH in SLE. Differences were considered signifi-
cant at P , 0.05.
Results
Demographic data of all SLe patients  
are shown in (Table 1)
Comparison of patients with and without 
pulmonary arterial hypertension
According  to  Doppler  echocardiographic  findings, 
PAH was detected in 8 patients (10.8%) out of   seventy 
four  SLE  patients.  PASP  ranged  from  34  mmHg 
to  61.2  mmHg  (43.19  ±  9.28).  SLE  patients  were 
classified into two groups:
•	 Group I: included 8 patients who had PAH: 7 adult-
onset SLE (aged from 19 to 30 yr) and 1 juvenile 
SLE (aged 12 years).
•	 Group II: included: 66 patients who had no PAH 
(50 adult-onset SLE, 9 childhood-onset SLE and 
7 juvenile SLE).
Comparison of patients with and without PAH 
to  find  if  there’s  any  association  of  PAH  with 
inflammatory,  SLE-related  or  other  risk  factors 
for  pulmonary  arterial  hypertension  had  showed 
that,  no  significant  differences  between  the  two 
groups  regarding,  demographic  and  clinical 
features  (Table  2),  while  laboratory  parameters 
had significantly higher frequencies of rheumatoid 
factor  and  anti-cardiolipin  antibodies  in  patients 
with PAH (P = 0.02, P = 0.008 respectively) as in 
(Table 3).
No  signs  of  vasculitis,  anti-phospholipid  syn-
drome and/or lung affection were found in patients 
with PAH.
Pulmonary  artery  pressure  was  differed  signifi-
cantly between the two groups subset (P , 0.001). Kamel et al
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Table 1. Demographic data of all SLe patients.
sLe patients (n =	74)
Adult sLe (n =	66) Juvenile sLe   
(n = 8) Adult-onset sLe  
(n =	57)
childhood-onset  
sLe (n =	9)
Age (yr)
  range 19–45 19–23 11–15
  Mean ± SD 28.14 ± 7.10 20.78 ± 1.39 13.56 ± 1.64
Duration of the disease (yr)
  range 0.3–16 3–12 0.1–4
  Mean ± SD 4.21 ± 3.46 5.89 ± 2.67 1.61 ± 1.74
Age at onset of the disease (yr)
  range 17–37.5 11–16 10–14.9
  Mean ± SD 23.93 ± 5.51 14.89 ± 1.83 11.95 ± 2.03
Table 2. Comparison of demographic and clinical features in SLe patients with pulmonary arterial hypertension versus 
those without.
sLe patients with pAH  
(n = 8, 10.8%)
sLe patients without pAH  
(n = 66, 89.2%)
P value#
Age (yr)
  range 12–30 11–45 0.4
  Mean ± SD 23.50 ± 5.95 25.93 ± 8.14
Age at onset of the disease (yr)
  range 11.7–29 10–37.5 0.9
  Mean ± SD 21.53 ± 5.97 21.54 ± 6.76
Duration of the disease (yr)
  range 0.3–6 0.1–16 0.05
  Mean ± SD 1.98 ± 1.86 4.39 ± 3.42
Fever 2 (25%) 25 (37.9%) 0.7
Malar rash 7 (87.5%) 54 (81.8%) 1
Photosensitivity 6 (75%) 51 (77.3%) 1
Alopecia 6 (75%) 42 (63.6%) 0.7
Oral ulcers 5 (62.5%) 48 (72.7%) 0.7
raynaud’s phenomenon 5 (62.5%) 18 (27.3%) 0.1
Arthralgia 7 (87.5%) 63 (95.5%) 0.4
Arthritis 5 (62.5%) 51 (77.3%) 0.4
Myalgia 5 (62.5%) 46 (69.7%) 0.7
Pleurisy 0 11 (16.7%) 0.6
renal affection
  Proteinuria 2 (25%) 34 (51.5%) 0.1
  Casts 1 (12.5%) 24 (36.4%) 0.1
eye affection 0 1 1
SLeDAI
  range 6–24 0–39 0.2
  Mean ± SD 12.50 ± 5.55 17.18 ± 8.93
note: #Chi-squared or Student’s t-test.
Abbreviations: PAh, pulmonary arterial hypertension; SLeDAI, SLe disease activity index.
The degree of pulmonary arterial hypertension was 
mild in 5, moderate in 2, and severe in one patient as 
shown in (Table 4). Different degrees of pulmonary 
hypertension as found in our patients are represented 
in (Fig. 1A–C).
Odds ratio of possible risk factors for development 
of PAH in SLE patients are shown in (Table 5).
Linear regression (stepwise method) was performed 
to evaluate all clinical and laboratory parameters. Among 
all factors, both rheumatoid   factor and ACL positivity Asymptomatic pulmonary hypertension in SLe
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were significantly associated with   occurrence of PAH in 
SLE (P = 0.007, P = 0.006 respectively) (Table 5).
No  significant  correlations  were  found  between 
pulmonary  artery  pressure,  disease  duration,  SLE-
DAI, ESR, and anti-ds DNA.
Table  6  summarizes  clinical  data,  laboratory 
features and PASP in SLE patients with PAH.
Discussion
  Systemic lupus erythematosus is an autoimmune disease 
with multiple organ involvement. Part of these patients 
represents variable degrees of pulmonary hypertension.15 
Pulmonary  hypertension  in  lupus  patients  has  been 
described since 1973.16–18 The prevalence rate of PAH 
in SLE patients ranges from 0.5% to 14%.19,20 In a serial 
study of 28 patients with SLE, the prevalence of PH 
measured by echocardiogram increased from 14% to 
43% with 5 years of follow-up.21
Prabu et al22 provides important data on the preva-
lence of PAH in a large cohort of SLE patients. The 
prevalence of PAH was found to be 4.2%, which was 
based  on  echocardiographic  screening.  Moreover, 
only 3 of the 12 patients had severe disease [systolic 
pulmonary  arterial  pressure  (PAP)  .40  mmHg]. 
These results are of particular interest, because the 
cohort, in contrast to other reports, has a community, 
non-  tertiary  background  and  seems  not  biased  by 
the patient selection, and therefore might very well 
Table 3. Comparison of laboratory features in SLe patients with pulmonary arterial hypertension versus those without.
sLe patients  
with pAH  
(n = 8, 10.8%)
sLe patients  
without  
pAH (n =	66, 89.2%)
P value#
hb (gm %)
  range 8.3–12.5 6.0–13.4 0.2
  Mean ± SD 10.91 ± 1.26 10.22 ± 1.55
WBC (mm3)
  range 3.6–5.8 × 103 2.2–10.7 × 103 0.6
  Mean ± SD 4.81 × 10³ ± 0.78 5.18 × 10³ ± 2.13
Platelets (mm3)
  range 227–398 × 103 74–467 × 103 0.6
  Mean ± SD 284.25 × 103 ± 63.34 × 103 270.64 × 103 ± 81.23 × 103
eSr (mm/h)
  range 34–115 16–143 0.2
  Mean ± SD 86.25 ± 34.02 70.80 ± 31.25
+ve rheumatoid factor 4 (50%) 8 (12.1%) 0.02*
+ve AnA 8 (100%) 64 (97%) 1
+ve Anti-ds DnA 3 (37.5%) 39 (59.1%) 0.3
+ve ACL 7 (87.5%) 24 (36.4%) 0.008**
Serum urea (mg/dl)
  range 14–126 10–187 0.4
  Mean ± SD 37.25 ± 36.55 49.11 ± 35.73
Serum creatinine (mg/dl)
  range 0.5–7.5 0.1–9.7 0.6
  Mean ± SD 1.53 ± 2.42 1.18 ± 1.49
Urine examination
  Proteinuria (gm/24 h) 0–12 0–15.6 0.8
1.59 ± 4.21 1.39 ± 2.53
  Casts
    granular 1 (12.5%) 12 (18.2%) 0.5
    hyaline 0 6 (9.1%)
    h&g 0 6 (9.1%)
Pyuria 3 (37.5%) 25 (37.9%) 1
hematuria 1 (12.5%) 18 (27.3%) 0.7
notes: *Significant P , 0.05; **highly significant P , 0.01; #chi-squared or Student’s t-test.
Abbreviations: PAh, pulmonary arterial hypertension; hb, haemoglobin; WBCs, white blood cells; eSr, erythrocyte sedimentation rate; AnA, antinuclear 
antibody; ACL, anti cardiolipin antibodies.Kamel et al
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be considered as representative of the general SLE 
population.
Yeh  et  al7  reported  the  prevalence  of  PAH  in 
juvenile SLE patients which range from 4% to 8% 
using  transthoracic  echocardiography.  Yet,  there 
are  no  studies  using  Doppler  echocardiography 
as  a  screening  tool  for  detection  of  asymptomatic 
pulmonary hypertension in juvenile SLE patients.
Doppler  echocardiography  is  the  most  widely 
available technology among the noninvasive imaging 
methods. Echocardiography provides both estimates 
of pulmonary artery pressure and an assessment of 
cardiac structure and function. These features justify 
its application as the most commonly used screening 
tool in patients with suspected PAH.9
In  the  present  study,  Doppler  echocardiography 
was used as a screening tool for detection of asymp-
tomatic pulmonary hypertension in SLE patients. PAH 
was found in 8 of 74 SLE female patients (10.8%), 
they were 7 adult-onset SLE (aged from 19 to 30 yr) 
and 1 juvenile SLE (aged 12 years).
Asherson et al23 have reported that, patients with 
SLE-PH are predominantly women of child-bearing 
potential aged from 18 to 40 years with a 10 to 1 ratio 
of female over male.
Foïs et al24 reported that systolic PAP . 35 mmHg 
in 12 (13%) out of 93 SLE patients, 10 women and 
2 men.
In the present study, Raynaud’s phenomenon was 
found in 5 adult-onset SLE patients with pulmonary 
hypertension (62.5%). In agreement with our results 
Haas20 reported that up to 58% of 105 patients (most 
of whom were female) with both PH and SLE had 
Raynaud’s  phenomenon.  Asherson  et  al25  found 
Raynaud’s phenomenon in 50% of adult SLE raising 
the possibility of vasospasm as an aetiological factor. 
However  Asherson  et  al23  reported  that  75%  of 
patients with SLE-PH have Raynaud’s phenomenon, 
which is higher than the expected rate of 25% among 
all patients with SLE.
The striking correlation between the occurrence of 
Raynaud’s phenomenon and SLE-PH suggests that 
Table 4. Comparison of eChO features in SLe patients with pulmonary arterial hypertension versus those without.
sLe patients  
with pAH  
(n = 8, 10.8%)
sLe patients  
without pAH  
(n = 66, 89.2%)
P value#
Pulmonary artery systolic pressure (mmhg)
  range 34–61.02 22–29 ,0.001***
  Mean ± SD 43.19 ± 9.28 26.19 ± 1.89
Degree of Pulmonary hypertension
  Mild 5 (62.5%) – –
  Moderate 2 (25%) –
  Severe 1 (12.5%) –
right ventricular dilatation 1 (12.5%) – –
Valvular thickening: 3 (37.5%) 11 (16.7%) 0.2
– Mitral thickening 3 (37.5%) 9 (13.6%) 0.1
– Aortic thickening 2 (25%) 5 (7.6%) 0.2
Degree of tricuspid regurge
  Mild 1 (12.5%) 18 (27.3%) ,0.001***
  Moderate 5 (62.5%) – –
  Severe 2 (25%) – –
Mitral stenosis 0 0 –
Mitral regurgitation 3 (37.5%) 11 (16.7%) 0.2
Aortic stenosis 0 0 –
Aortic regurgitation 0 0 –
Mild pericardial effussion 2 (25%) 12 (18.2%) 0.6
ejection fraction
  range 58%–68% 48%–80% 0.6
  Mean ± SD 61.75% ± 3.49% 62.98% ± 7.05%
notes: #Chi-squared or Student’s t-test; ***very highly significant P , 0.001.
Abbreviation: PAh, pulmonary arterial hypertension.Asymptomatic pulmonary hypertension in SLe
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pulmonary arterial vasospasm may also be involved in 
the pathogenesis of SLE-PH. Raynaud’s phenomenon 
is part of a systemic vascular response that includes a 
decrease in size of the pulmonary capillary bed, which 
may in turn result in muscular necrosis and secondary 
inflammation.26
No signs of vasculitis were found in any case in 
the  present  study.  However, Asherson  et  al23  have 
reported that one-third of patients with pulmonary 
hypertension in their study had evidence of peripheral 
cutaneous  vasculitis,  livedo  reticularis,  and  digital 
gangrene.
In the present study, SLE patients with PAH showed 
statistically  significant  higher  number  of  cases  with 
positive rheumatoid factor (RF) (50%) and positive 
anticardiolipin  antibodies  (87.5%)  in  comparison 
to SLE patients without PAH (P = 0.02, P = 0.008 
  respectively). All SLE patients with PAH were positive 
for ANA. In agreement with our results Asherson et al 
and Wilson et al reported that patients with SLE-PH 
are universally positive for ANA. Antibodies to ribo-
nuclear protein (RNP) and rheumatoid factor (RF) are 
often present in SLE-PH, although no pathogenic role 
has been postulated. The prevalence of RF has been 
reported to be as high as 50% to 80% in SLE-PH. The 
frequency of PH in patients with SLE and positive 
antiphospholipid antibodies is considerably higher than 
in  patients  with  SLE  and  negative  antiphospholipid 
antibodies (83% versus 25%).23,27
Lian et al28 have found positive rheumatoid factor in 
46.3% and positive anticardiolipin antibodies in 53.7% 
of patients with SLE-PH. However, Foïs et al24 have 
reported a very high frequency of anticardiolipin anti-
bodies (75%) in their patients and they suggested that 
these autoantibodies might facilitate the formation of 
microthrombi in the pulmonary vasculature and thereby 
contribute  to  sPAP  elevation,  but  the  relationship 
between them and PH in SLE remains controversial.
In our SLE patients with PAH, Doppler echocar-
diography  detected  elevated  pulmonary  artery 
  systolic pressure in 8 patients (10.8%), being mild 
in 5,   moderate in 2, and severe in one patient, right 
ventricular dilatation in 1 patient, (12.5%), valvular 
thickening in 3 patients, (37.5%), tricuspid regurge 
(mild in 1, moderate in 5, and severe in 2 patients), 
Figure  1.  (A)  24  years  old  female  with  SLe  duration  6  years. 
PASP = 37.44 mmhg, mild degree. (b) 19 years old female with SLe dura-
tion 1 year. PASP = 49.06 mmhg, moderate degree. (c) 22 years old female 
with SLe duration 2.5 years. PASP = 61.02 mmhg, severe degree.
Table  5.  Possible  risk  factors  that  predict  pulmonary 
  arterial hypertension in SLe patients.
Risk factors Odds ratio 95% cI P value#
renal disease 0.28 0.05–1.48 0.06
raynaud’s 
phenomenon
4.44 0.96–20.53 0.08
Positive  
rheumatoid  
factor
7.25 1.5–34.87 0.007**
Positive ACL 12.25 1.42–105.64 0.006**
notes: #Linear regression analysis; **highly significant P , 0.01.Kamel et al
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PAH in SLE (P = 0.007, P = 0.006 respectively) in the 
linear regression analysis.
Study  findings  by  Robbins  et  al29  indicate  that 
the  duration  of  SLE  does  not  correlate  with  the 
development of PAH, although many patients with 
SLE  develop  PAH  within  the  first  5  years.  These 
findings coincided with our results, as the duration of 
SLE was not correlated with PAH and SLE patients 
with PAH had shorter disease duration (0.3–6 yr) in 
comparison to SLE patients without PAH (0.1–16 yr), 
but the difference not statistically significant.
SLE disease related risk factors, the disease activ-
ity  score  (SLEDAI),  ESR,  anti-ds  DNA  and  renal 
affection in SLE patients enrolled in the present study 
Table 6. Cases of SLe patients with pulmonary arterial hypertension.
no. Age (yr) Duration of the  
disease (yr)
extra-pulmonary  
manifestations
Laboratory  
investigations
pAsp (mmHg),  
degree of pAH
1 24 6 Malar rash, alopecia,  
oral ulcers, arthralgia
eSr 34 mm/h  
+ve AnA  
+ve ACL  
Pyuria,  
hematuria
37.44, mild
2 22 2.5 Malar rash, photosensitivity,  
oral ulcers, raynaud’s phenomenon
eSr 34 mm/h  
+ve rF  
+ve AnA  
+ve DnA  
+ve ACL
61.02, severe
3 26 1 Alopecia, raynaud’s phenomenon,  
arthralgia, myalgia, arthritis
eSr 90 mm/h  
+ve AnA  
+ve DnA  
+ve ACL  
Pyuria,  
casts, proteinuria
34, mild
4 30 1 Malar rash, photosensitivity, alopecia,  
raynaud’s phenomenon, oral ulcers,  
arthralgia, myalgia, arthritis
eSr 115 mm/h  
+ve rF  
+ve AnA  
+ve ACL
50, moderate
5 25 3 Malar rash, photosensitivity, alopecia,  
raynaud’s phenomenon, arthralgia,  
myalgia
eSr 89 mm/h  
+ve AnA  
+ve DnA  
Pyuria,  
proteinuria
39, mild
6 19 1 Malar rash, photosensitivity, alopecia,  
raynaud’s phenomenon, fever,  
arthralgia, arthritis
eSr 98 mm/h  
+ve rF  
+ve AnA  
+ ve ACL
49.06, moderate
7 30 1 Malar rash, photosensitivity, alopecia,  
oral ulcers, arthralgia, myalgia, arthritis
eSr 115 mm/h  
+ve AnA  
+ve ACL
36, mild
8 12 0.3 Malar rash, photosensitivity, oral ulcers,  
arthralgia, myalgia, arthritis
eSr 115 mm/h  
+ve rF  
+ve AnA  
+ve ACL
39, mild
and even mild pericardial effusion in 2 patients, (25%) 
before symptom onset.
Lian et al28 reported that, Raynaud’s phenomenon, 
anticardiolipin  antibodies,  and  anti-U1RNP  were 
associated with increased odds ratio (OR = 3.204, 
OR  =  3.753,  OR  =  5.393  respectively),  and  were 
considered  as  significant  independent  predictors 
of PAH in SLE (P = 0.01, P = 0.004, P = 0.001 
respectively).  But  in  the  current  study,  Raynaud’s 
phenomenon, rheumatoid factor, and anti-cardiolipin 
antibodies were associated with increased risk for PAH 
(OR = 4.44, OR = 7.25, OR = 12.25 respectively). 
While only positive rheumatoid factor and positive 
ACL were significantly associated with occurrence of Asymptomatic pulmonary hypertension in SLe
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2011:4  85
did not differ significantly between patients with PAH 
and those without, and they weren’t correlated with 
PAH. In agreement with our results, Asherson et al23 
and Robbins et al29 reported that PH was unrelated 
to the severity or activity of SLE such as high anti 
ds-DNA and/or grossly elevated ESR, and can occur 
when non-pulmonary disease activity is quiescent.
conclusion
In our SLE patients, Doppler echocardiography could 
detect  elevated  pulmonary  artery  systolic  pressure 
in  10.8%,  degree  of  pulmonary  hypertension,  right 
ventricular  dilatation,  valvular  thickening,  tricuspid 
regurge,  and  even  mild  pericardial  effusion  before 
symptom onset. SLE patients with PAH showed signif-
icant higher number of cases with positive rheumatoid 
factor (50%) and positive anticardiolipin antibodies 
(87.5%) in comparison to SLE patients without PAH.
Echocardiography should be performed routinely 
once a year (as a screening tool) and consideration 
should  be  given  to  screening  SLE  patients  with 
positive anti-cardiolipin antibodies, and rheumatoid 
  factor; as they were significant predictors of pulmo-
nary hypertension in SLE.
Further study is required to determine if patients 
with  asymptomatic  pulmonary  hypertension  will 
benefit  from  therapy  in  terms  of  morbidity  and 
mortality.
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